Stock AnalizGoodRx Holdings, Inc. GDRX
EDP Services · IPO 2020 · data as of November 13, 2026
GoodRx Holdings, Inc. (GDRX) is a technology company listed in the US with a market value of about $1.2B. In the twelve months to June 30, 2026 it had revenue of $785M and net income of $16M, a net margin of 2.1%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (3/5); the weakest is track record (0/5).
Key numbers: a P/E of 71.2, a price to free cash flow of 6.2, 5-year revenue growth of 8% a year, a 5-year average ROIC of 1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 33% below the current price.
Score: 1.4 / 5
Checks passed
- P/FCF below 20
- Profit margin improving
- Strong R&D investment or growth above 20%
- Positive free cash flow
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $785M | $797M | $792M | $750M | $767M | $745M | $551M | $388M | $250M |
| Net income | $16M | $30M | $16M | -$9M | -$33M | -$25M | -$294M | $66M | $44M |
| Free cash flow | $197M | $164M | $183M | $137M | $143M | $174M | $111M | $82M | $44M |
| EPS (diluted) | $0.04 | $0.09 | $0.04 | $-0.02 | $-0.08 | $-0.06 | $-1.07 | $0.18 | $0.12 |
| Net margin | 2.1% | 3.8% | 2.1% | -1.2% | -4.3% | -3.4% | -53.3% | 17.0% | 17.5% |
| ROIC | — | 4.0% | 2.7% | -1.5% | 0.1% | 0.7% | -18.6% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $3.95, 11% above the current price; targets range from $2.65 to $5.00; the consensus rating is “Hold”; expected EPS is $0.30 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is GoodRx’s P/E ratio?
About 71.2, based on the last twelve months of diluted earnings per share (forward P/E about 10.7).
Is GoodRx stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 33% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does GoodRx pay a dividend?
Not currently.
Is GoodRx a good stock to buy?
We do not give buy or sell advice. GoodRx scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.